BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2628-2634. [PMID: 21606433 DOI: 10.1200/jco.2010.32.1877] [Cited by in Crossref: 86] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, Xin G, Pei L, Gu S, Li X, Zhao X. Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol 2014;2:245-51. [PMID: 24649341 DOI: 10.3892/mco.2013.230] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
2 Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4:117-132. [PMID: 23386910 DOI: 10.7150/jca.4925] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
3 Gong W, Liu Y, Preis S, Geng X, Petit-Courty A, Kiechle M, Muckenhuber A, Dreyer T, Dorn J, Courty Y, Magdolen V. Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients. Mol Med 2020;26:19. [PMID: 32028882 DOI: 10.1186/s10020-020-0145-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ahn SG, Park JT, Lee HM, Lee HW, Jeon TJ, Han K, Lee SA, Dong SM, Ryu YH, Son EJ, Jeong J. Standardized uptake value of ¹⁸F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden. Breast Cancer Res 2014;16:502. [PMID: 25551703 DOI: 10.1186/s13058-014-0502-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
5 Cocciolone V, Cannita K, Calandrella ML, Ricevuto E, Baldi PL, Sidoni T, Irelli A, Paradisi S, Pizzorno L, Resta V, Bafile A, Alesse E, Tessitore A, Ficorella C. Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis. Oncotarget 2017;8:72031-43. [PMID: 29069766 DOI: 10.18632/oncotarget.18526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Garg M, Nagpal N, Sidhu DS, Singh A. Effect of Lump Size and Nodal Status on Prognosis in Invasive Breast Cancer: Experience from Rural India. J Clin Diagn Res 2016;10:PC08-11. [PMID: 27504343 DOI: 10.7860/JCDR/2016/20470.8039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Castrellon AB, Pidhorecky I, Valero V, Raez LE. The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncol Rev 2017;11:324. [PMID: 28382189 DOI: 10.4081/oncol.2017.324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
8 Weitsman G, Lawler K, Kelleher MT, Barrett JE, Barber PR, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis ID, Woodman N, Ofo E, Ameer-Beg SM, Irshad S, Condeelis J, Gillett CE, Ellis PA, Vojnovic B, Coolen AC, Ng T. Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients. Biochem Soc Trans 2014;42:1498-505. [PMID: 25399560 DOI: 10.1042/BST20140165] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
9 Yin L, Shuang H, Sheng C, Liang H, Sun XJ, Yang WT, Shao ZM. The Prognostic Value of Nodal Staging in Triple-Negative Breast Cancer - A Cohort from China. Sci Rep 2018;8:9007. [PMID: 29899402 DOI: 10.1038/s41598-018-23999-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Gonçalves H Jr, Guerra MR, Duarte Cintra JR, Fayer VA, Brum IV, Bustamante Teixeira MT. Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort. Clin Med Insights Oncol 2018;12:1179554918790563. [PMID: 30083066 DOI: 10.1177/1179554918790563] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
11 Liu J, Xiao Y, Wei W, Guo JX, Liu YC, Huang XH, Zhang RX, Wu YJ, Zhou J. Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer. Exp Ther Med 2015;10:379-85. [PMID: 26170966 DOI: 10.3892/etm.2015.2489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chen HL, Ding A, Wang FW. Prognostic effect analysis of molecular subtype on young breast cancer patients. Chin J Cancer Res 2015;27:428-36. [PMID: 26361413 DOI: 10.3978/j.issn.1000-9604.2015.08.02] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
13 Li M, Li A, Zhou S, Xu Y, Xiao Y, Bi R, Yang W. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer 2018;18:4. [PMID: 29291717 DOI: 10.1186/s12885-017-3916-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
14 Shen S, Sun Q, Liang Z, Cui X, Ren X, Chen H, Zhang X, Zhou Y. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One 2014;9:e100664. [PMID: 24945253 DOI: 10.1371/journal.pone.0100664] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
15 Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat 2012;134:683-92. [PMID: 22547108 DOI: 10.1007/s10549-012-2072-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
16 Wang H, Wang L, Song Y, Wang S, Huang X, Xuan Q, Kang X, Zhang Q. CD44+/CD24- phenotype predicts a poor prognosis in triple-negative breast cancer. Oncol Lett 2017;14:5890-8. [PMID: 29113223 DOI: 10.3892/ol.2017.6959] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
17 Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 2011;18:3164-73. [PMID: 21947595 DOI: 10.1245/s10434-011-1920-z] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
18 Zaidi S, Hussain S, Verma S, Veqar Z, Khan A, Nazir SU, Singh N, Moiz JA, Tanwar P, Srivastava A, Rath GK, Mehrotra R. Efficacy of Complementary Therapies in the Quality of Life of Breast Cancer Survivors. Front Oncol 2017;7:326. [PMID: 29376027 DOI: 10.3389/fonc.2017.00326] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
19 Walsh EM, Shalaby A, O'Loughlin M, Keane N, Webber MJ, Kerin MJ, Keane MM, Glynn SA, Callagy GM. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. Breast Cancer Res Treat. 2019;174:1-13. [PMID: 30488345 DOI: 10.1007/s10549-018-5066-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
20 Wang JW, Wei XL, Dou XW, Huang WH, Du CW, Zhang GJ. The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer. Oncol Lett 2018;15:8749-55. [PMID: 29805613 DOI: 10.3892/ol.2018.8442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
21 He M, Zhang JX, Jiang YZ, Chen YL, Yang HY, Tang LC, Shao ZM, Di GH. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. Oncotarget 2017;8:44870-80. [PMID: 28496004 DOI: 10.18632/oncotarget.17413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ma F, Ding X, Fan Y, Ying J, Zheng S, Lu N, Xu B. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer. PLoS One 2014;9:e112765. [PMID: 25393310 DOI: 10.1371/journal.pone.0112765] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
23 Liu D, Lan Y, Zhang L, Wu T, Cui H, Li Z, Sun P, Tian P, Tian J, Li X. Nomograms for Predicting Axillary Lymph Node Status Reconciled With Preoperative Breast Ultrasound Images. Front Oncol 2021;11:567648. [PMID: 33898303 DOI: 10.3389/fonc.2021.567648] [Reference Citation Analysis]
24 Avery-Kiejda KA, Mathe A, Scott RJ. Genome-wide miRNA, gene and methylation analysis of triple negative breast cancer to identify changes associated with lymph node metastases. Genom Data 2017;14:1-4. [PMID: 28736703 DOI: 10.1016/j.gdata.2017.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim H, Yin T, Fan S, Shen Q. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene 2018;37:5292-304. [PMID: 29855616 DOI: 10.1038/s41388-018-0340-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 18.7] [Reference Citation Analysis]
26 Amirkhani Namagerdi A, d'Angelo D, Ciani F, Iannuzzi CA, Napolitano F, Avallone L, De Laurentiis M, Giordano A. Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology. Front Oncol 2020;10:563779. [PMID: 33282730 DOI: 10.3389/fonc.2020.563779] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, Wimberger P, Link T, Müller E, Fehm T, Abel M, Stein S, Bohle R, Endrikat J, Solomayer EF. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol 2016;142:1369-76. [PMID: 27008006 DOI: 10.1007/s00432-016-2146-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
28 Pogoda K, Niwińska A, Murawska M, Pieńkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 2013;30:388. [PMID: 23292831 DOI: 10.1007/s12032-012-0388-4] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
29 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
30 Comen E, Morris PG, Norton L. Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer. J Mammary Gland Biol Neoplasia 2012;17:241-9. [PMID: 23011603 DOI: 10.1007/s10911-012-9267-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
31 Yuan C, Luo X, Duan S, Guo L. Long noncoding RNA LINC00115 promotes breast cancer metastasis by inhibiting miR-7. FEBS Open Bio 2020;10:1230-7. [PMID: 32175684 DOI: 10.1002/2211-5463.12842] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
32 Zumsteg ZS, Morrow M, Arnold B, Zheng J, Zhang Z, Robson M, Traina T, McCormick B, Powell S, Ho AY. Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Ann Surg Oncol 2013;20:3469-76. [PMID: 23686101 DOI: 10.1245/s10434-013-3011-9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
33 Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF, Scott RJ. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer 2014;14:51. [PMID: 24479446 DOI: 10.1186/1471-2407-14-51] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 7.7] [Reference Citation Analysis]
34 Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, Huang O, He JR, Chen W, Li Y, Shen K, Zhu L. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget 2016;7:31079-87. [PMID: 27145269 DOI: 10.18632/oncotarget.9075] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
35 Hayashi Y, Satake H, Ishigaki S, Ito R, Kawamura M, Kawai H, Iwano S, Naganawa S. Kinetic volume analysis on dynamic contrast-enhanced MRI of triple-negative breast cancer: associations with survival outcomes. Br J Radiol 2020;93:20190712. [PMID: 31821036 DOI: 10.1259/bjr.20190712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lee SB, Kim HK, Choi Y, Ju YW, Lee HB, Han W, Noh DY, Son BH, Ahn SH, Kim KS, Nam SJ, Kim EK, Park HY, Park WC, Lee JW, Moon HG. Dynamic and subtype-specific interactions between tumour burden and prognosis in breast cancer. Sci Rep 2020;10:15445. [PMID: 32963275 DOI: 10.1038/s41598-020-72033-3] [Reference Citation Analysis]
37 Jin L, Lim M, Zhao S, Sano Y, Simone BA, Savage JE, Wickstrom E, Camphausen K, Pestell RG, Simone NL. The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster. Breast Cancer Res Treat 2014;146:41-50. [PMID: 24863696 DOI: 10.1007/s10549-014-2978-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
38 Huang L, Liu Z, Chen S, Liu Y, Shao Z. A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index. PLoS One 2013;8:e83081. [PMID: 24340082 DOI: 10.1371/journal.pone.0083081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
39 El Saghir NS, Assi HA, Jaber SM, Khoury KE, Nachef Z, Mikdashi HF, El-Asmar NS, Eid TA. Outcome of Breast Cancer Patients Treated outside of Clinical Trials. J Cancer 2014;5:491-8. [PMID: 24959302 DOI: 10.7150/jca.9216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bhat S, Gardi N, Hake S, Kotian N, Sawant S, Kannan S, Parmar V, Desai S, Dutt A, Joshi NN. Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients. J Cancer Res Clin Oncol 2017;143:1745-56. [PMID: 28470472 DOI: 10.1007/s00432-017-2431-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
41 Wang XX, Jiang YZ, Li JJ, Song CG, Shao ZM. Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. Oncotarget 2016;7:46636-45. [PMID: 27203673 DOI: 10.18632/oncotarget.9432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
42 Urru SAM, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, Murgia A, Sanges F, Pira G, Manca A, Palmas D, Floris M, Asunis AM, Atzori F, Carru C, D'Incalci M, Ghiani M, Marras V, Onnis D, Santona MC, Sarobba G, Valle E, Canu L, Cossu S, Bulfone A, Rocca PC, De Miglio MR, Orrù S. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer 2018;18:56. [PMID: 29310602 DOI: 10.1186/s12885-017-3969-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
43 Narod SA, Iqbal J, Jakubowska A, Huzarski T, Sun P, Cybulski C, Gronwald J, Byrski T, Lubinski J. Are two-centimeter breast cancers large or small? Curr Oncol 2013;20:205-11. [PMID: 23904761 DOI: 10.3747/co.20.1364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
44 Sun W, Li C, Liu M, Liu W, Yang C, Cai LI. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. Oncol Lett 2016;11:2320-6. [PMID: 26998170 DOI: 10.3892/ol.2016.4176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Hallett RM, Dvorkin-Gheva A, Bane A, Hassell JA. A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep 2012;2:227. [PMID: 22355741 DOI: 10.1038/srep00227] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
46 Wei LY, Zhang XJ, Wang L, Hu LN, Zhang XD, Li L, Gao JN. A Six-Epithelial-Mesenchymal Transition Gene Signature May Predict Metastasis of Triple-Negative Breast Cancer. Onco Targets Ther 2020;13:6497-509. [PMID: 32753890 DOI: 10.2147/OTT.S256818] [Reference Citation Analysis]
47 Saberi A, Danyaei A, Neisi N, Dastoorpoor M, Tahmasbi Birgani MJ. MiR-328 May be Considered as an Oncogene in Human Invasive Breast Carcinoma. Iran Red Crescent Med J 2016;18:e42360. [PMID: 28203454 DOI: 10.5812/ircmj.42360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
48 Min SK, Lee SK, Woo J, Jung SM, Ryu JM, Yu J, Lee JE, Kim SW, Chae BJ, Nam SJ. Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. J Breast Cancer 2021;24:75-84. [PMID: 33634622 DOI: 10.4048/jbc.2021.24.e4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Hartge P, Speyer JL. Finding ovarian cancer. J Natl Cancer Inst 2012;104:82-3. [PMID: 22247023 DOI: 10.1093/jnci/djr518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
50 Liu Q, Xing P, Dong H, Zhao T, Jin F. Preoperative assessment of axillary lymph node status in breast cancer patients by ultrasonography combined with mammography: A STROBE compliant article. Medicine (Baltimore) 2018;97:e11441. [PMID: 30045266 DOI: 10.1097/MD.0000000000011441] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
51 Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer 2019;120:1129-36. [PMID: 31114020 DOI: 10.1038/s41416-019-0486-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
52 Inari H, Teruya N, Kishi M, Horii R, Akiyama F, Takahashi S, Ito Y, Ueno T, Iwase T, Ohno S. Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy. Cancers (Basel) 2020;12:E2633. [PMID: 32942650 DOI: 10.3390/cancers12092633] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Stathopoulos GP, Malamos NA, Markopoulos C, Polychronis A, Armakolas A, Rigatos S, Yannopoulou A, Kaparelou M, Antoniou P. The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anticancer Drugs 2014;25:950-7. [PMID: 24949917 DOI: 10.1097/CAD.0000000000000123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
54 Zuckerman NS, Yu H, Simons DL, Bhattacharya N, Carcamo-Cavazos V, Yan N, Dirbas FM, Johnson DL, Schwartz EJ, Lee PP. Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int J Cancer 2013;132:2537-47. [PMID: 23136075 DOI: 10.1002/ijc.27933] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
55 Turker I, Arslan UY, Yazici O, Uyeturk U, Oksuzoglu B, Budakoglu B, Özdemir N, Sonmez OU, Helvaci K, Esbah O, Bal O, Ekinci AS, Zengin N. Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients. Breast Care (Basel) 2014;9:421-7. [PMID: 25759625 DOI: 10.1159/000366438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Roberti MP, Arriaga JM, Bianchini M, Quintá HR, Bravo AI, Levy EM, Mordoh J, Barrio MM. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther. 2012;13:1123-1140. [PMID: 22825326 DOI: 10.4161/cbt.21187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]